Clinical Trials Logo

Grass Allergy clinical trials

View clinical trials related to Grass Allergy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02292875 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune Grass Follow on Study

Start date: April 2014
Phase: Phase 2
Study type: Observational

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy. The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all dosing visits in study TG002 approximately two years after the start of treatment.

NCT ID: NCT02075138 Completed - Rhinoconjunctivitis Clinical Trials

Grass Observational Study

Start date: April 2014
Phase: N/A
Study type: Observational

Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans, including asthma, allergic rhinitis, conjunctivitis and dermatitis. The purpose of the current study is to evaluate allergy symptoms and allergy medication in subjects with grass-related rhinoconjunctivitis.

NCT ID: NCT01923779 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune Grass Follow on Study

Start date: May 2013
Phase: N/A
Study type: Observational

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy. The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all dosing visits in study TG002 approximately one year after the start of treatment.

NCT ID: NCT01728285 Completed - Allergic Rhinitis Clinical Trials

Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis

GT-17
Start date: March 2007
Phase: Phase 3
Study type: Interventional

Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases. GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken daily by patients. This study was aimed to establish if a device with the characteristics of a mechanical dispenser (Memozax®) could improve adherence to treatment in subjects with hay fever due to allergy to grass

NCT ID: NCT01385800 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune Grass Exposure Unit Study

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy. This study will look at the efficacy, safety and tolerability of three doses of ToleroMune Grass in grass allergic subjects following challenge with with grass in an Environmental Exposure Unit (EEU).

NCT ID: NCT01123252 Completed - Asthma Clinical Trials

Seasonal Allergic Rhinitis Study

SAR
Start date: September 2010
Phase: Phase 2
Study type: Interventional

The study aims to examine the effect of probiotics on the clinical symptoms of allergic rhinitis and to elucidate some of the immunological mechanisms involved.